专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006128082A3 BIOMARKERS FOR BREAST CANCER 审中-公开
标题翻译：乳腺癌生物标志物
公开(公告)号：WO2006128082A3
公开(公告)日：2007-03-01
申请号：PCT/US2006020643
申请日：2006-05-25
申请人： UNIV JOHNS HOPKINS , LI JINONG , SUKUMAR SARASWATI , CHAN DANIEL W
发明人： LI JINONG , SUKUMAR SARASWATI , CHAN DANIEL W
IPC分类号： G01N33/574 , A61K39/00 , C07K5/00 , G06F19/00
CPC分类号： G01N33/57415 , G01N2333/4721
摘要： The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non- breast cancer. The biomarkers can be detected by SELDI mass spectrometry.
摘要翻译：本发明提供了可用于评估患者乳腺癌状态的基于蛋白质的生物标志物和生物标志物组合。特别地，本发明的生物标志物可用于将受试者样品分类为乳腺癌或非乳腺癌。生物标志物可以通过SELDI质谱检测。

2. 发明申请

WO2012118915A3 COMPOSITIONS AND METHODS FOR TREATMENT OF TAMOXIFEN RESISTANT BREAST CANCER 审中-公开
标题翻译：用于治疗酪氨酸抗性乳腺癌的组合物和方法
公开(公告)号：WO2012118915A3
公开(公告)日：2012-11-22
申请号：PCT/US2012027185
申请日：2012-03-01
申请人： UNIV JOHNS HOPKINS , SUKUMAR SARASWATI , JIN KIDEOK
发明人： SUKUMAR SARASWATI , JIN KIDEOK
IPC分类号： C12N15/113 , A61K31/7088 , A61K48/00 , A61P35/00 , C12N15/63 , G01N33/15
CPC分类号： C12N15/113 , A61K31/713 , C12N15/1135 , C12N2310/14 , C12N2310/141 , C12Q1/6886 , C12Q1/6897
摘要： The inventors found that the gene, HOXB7, was frequently overexpressed in breast cancer, and is a major upstream regulator of events leading to tamoxifen resistance. The present invention provides double-stranded short interfering nucleic acid (siNA) molecules that targets the HOXB7 gene in cells, and also provides methods of use of this siNA molecule for methods of screening, diagnosis and prediction of treatment outcomes as well as treatment of cancer.
摘要翻译：发明人发现，基因HOXB7在乳腺癌中经常过表达，并且是导致他莫昔芬抗性的事件的主要上游调节剂。本发明提供靶向细胞中HOXB7基因的双链短干扰核酸（siNA）分子，并且还提供了该siNA分子用于筛选，诊断和预测治疗结果以及治疗癌症的方法。

3. 发明申请

WO2007136857A3 HOX COMPOSITIONS AND METHODS 审中-公开
标题翻译： HOX组合物和方法
公开(公告)号：WO2007136857A3
公开(公告)日：2008-11-20
申请号：PCT/US2007012183
申请日：2007-05-21
申请人： UNIV JOHNS HOPKINS , SUKUMAR SARASWATI , TAO ZHU , WU XINYAN , CHEN HEXIN
发明人： SUKUMAR SARASWATI , TAO ZHU , WU XINYAN , CHEN HEXIN
IPC分类号： A61K48/00
CPC分类号： A61K39/39558 , A61K31/7088 , A61K31/713 , A61K38/1709 , C07K14/47 , C12N15/113 , C12N2310/14
摘要： The present invention relates to compositions to treat HOXB7 related disorders. The invention also relates to methods treating HOXB7 related disorders. The invention further relates to kits for treating HOXB7 related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating HOXB7 related disorders in a subject.
摘要翻译：本发明涉及治疗HOXB7相关疾病的组合物。本发明还涉及治疗HOXB7相关疾病的方法。本发明还涉及用于治疗受试者中HOXB7相关疾病的试剂盒。本发明还涉及确定用于治疗受试者中HOXB7相关疾病的新疗法的方法。

4. 发明申请

WO2007136856A3 HEYL AS A THERAPEUTIC TARGET AND A DIAGNOSTIC MARKER FOR NEOPLASIA AND USES THEREFOR 审中-公开
标题翻译： HEYL作为治疗目标和诊断标记为NEOPLASIA及其用途
公开(公告)号：WO2007136856A3
公开(公告)日：2008-01-31
申请号：PCT/US2007012182
申请日：2007-05-21
申请人： UNIV JOHNS HOPKINS , SUKUMAR SARASWATI , HAN LIANGFENG
发明人： SUKUMAR SARASWATI , HAN LIANGFENG
IPC分类号： C07K16/00 , C12P21/08
CPC分类号： C12Q1/6886 , C07K16/3015 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G01N33/574 , G01N2333/4703
摘要： The invention generally features compositions and methods that are useful for treating or diagnosing a neoplasia, in particular breast neoplasia. The invention is based in part on the observation that the basic helix loop helix transcription factor HEYL was found to be overexpressed in breast cancer cells. Accordingly, the invention provides therapeutic compositions and methods for altering the levels and expression of HEYL of the invention, thereby treating a neoplasia, as well as compositions and methods for diagnosing a neoplasia.
摘要翻译：本发明通常具有可用于治疗或诊断瘤形成，特别是乳腺肿瘤的组合物和方法。本发明部分基于在乳腺癌细胞中发现基本螺旋环螺旋转录因子HEYL被过表达的观察。因此，本发明提供用于改变本发明HEYL的水平和表达的治疗组合物和方法，从而治疗瘤形成，以及用于诊断瘤形成的组合物和方法。

5. 发明申请

WO2005042713A2 QUANTITATIVE MULTIPLEX METHYLATION-SPECIFIC PCR 审中-公开
标题翻译：定量多元甲基化特异性PCR
公开(公告)号：WO2005042713A2
公开(公告)日：2005-05-12
申请号：PCT/US2004036012
申请日：2004-10-28
申请人： UNIV JOHNS HOPKINS , SUKUMAR SARASWATI , FACKLER MARY JO
发明人： SUKUMAR SARASWATI , FACKLER MARY JO
IPC分类号： C12N20060101 , C12P19/34 , C12Q1/68 , C12N
CPC分类号： C12Q1/6827 , C07H21/04 , C12Q1/6813 , C12Q1/686 , C12Q1/6886 , C12Q2600/154 , C12Q2600/16 , C12Q2561/113 , C12Q2537/164 , C12Q2537/143
摘要： Methods are provided for diagnosing in a subject a condition, such as a carcinoma, sarcoma or leukemia, associated with hypermethylation of genes by isolating the genes from tissue containing as few as 50 to 1000 tumor cells. Using quantitative multiplex methylation specific PCR (QM-MSP), multiple genes can be quantitatively evaluated from samples usually yielding sufficient DNA for analyses of only 1 or 2 genes. DNA sequences isolated from the sample are simultaneously co-amplified in an initial multiplex round of PCR, and the methylation status of individual hypermethylation-prone gene promoter sequences is then determined separately or in multiplex using a real time PCR round that is methylation status-specific. Within genes of the panel, the level of promoter hypermethylation as well as the incidence of promoter hypermethylation can be determined and the level of genes in the panel can be scored cumulatively. The QM-MSP method is adaptable for high throughput automated technology.
摘要翻译：提供了用于通过从含有少至50至1000个肿瘤细胞的组织中分离基因而在受试者诊断与基因的高甲基化相关的病症如癌，肉瘤或白血病的方法。使用定量多重甲基化特异性PCR（QM-MSP），可以从样品定量评估多个基因，通常产生足够的DNA用于仅分析1或2个基因。在初始多重PCR中同时共同扩增从样品中分离的DNA序列，然后使用甲基化状态特异性的实时PCR循环单独或多次测定单个高甲基化易基因启动子序列的甲基化状态。在小组的基因内，可以确定启动子超甲基化的水平以及启动子高甲基化的发生率，并且可以累积评估小组中的基因水平。 QM-MSP方法适用于高通量自动化技术。

6. 发明申请

WO2004091383A2 BREAST ENDOTHELIAL CELL EXPRESSION PATTERNS 审中-公开
标题翻译： BREAST内皮细胞表达模式
公开(公告)号：WO2004091383A2
公开(公告)日：2004-10-28
申请号：PCT/US2004009704
申请日：2004-03-31
申请人： SUKUMAR SARASWATI , MADDEN STEPHEN
发明人： SUKUMAR SARASWATI , MADDEN STEPHEN
IPC分类号： A61B20060101 , A61B1/00 , A61K38/17 , C12Q1/68 , G01N33/574 , A61B
CPC分类号： G01N33/57415 , A61K38/17 , A61K39/0011 , A61K39/39558 , C12Q1/6886 , C12Q2600/136 , G01N33/5011
摘要： To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
摘要翻译：为了更好地了解乳腺肿瘤血管发生，分离乳腺内皮细胞（ECs）并评估基因表达模式。比较来自正常乳腺组织和恶性乳腺组织的乳腺ECs的转录物，揭示了与肿瘤相关的乳腺内皮特异性升高的基因。这些结果证实，人乳腺肿瘤和正常内皮在分子水平上是不同的，对未来抗血管生成疗法的发展具有重要意义。

7. 发明公开

EP1907857A4 BIOMARKERS FOR BREAST CANCER 审中-公开
标题翻译：生物标志物用于乳腺癌
公开(公告)号：EP1907857A4
公开(公告)日：2009-08-05
申请号：EP06771418
申请日：2006-05-25
申请人： UNIV JOHNS HOPKINS
发明人： LI JINONG , SUKUMAR SARASWATI , CHAN DANIEL W
IPC分类号： G01N33/574 , A61K39/00 , C07K5/00 , G06F19/00
CPC分类号： G01N33/57415 , G01N2333/4721

8. 发明公开

EP2852690A4 A QUANTITATIVE MULTIPLEX METHYLATION SPECIFIC PCR METHOD- cMethDNA, REAGENTS, AND ITS USE 有权
标题翻译：定量MULTIPLEX甲基化特异性PCR CMETHDNA程序，试剂及其用途
公开(公告)号：EP2852690A4
公开(公告)日：2016-01-13
申请号：EP13794493
申请日：2013-05-22
申请人： UNIV JOHNS HOPKINS
发明人： SUKUMAR SARASWATI , FACKLER MARY JO , TEO WEI WEN , LOPEZ BUJANDA ZOILA ARELI
IPC分类号： C12Q1/68 , C12N15/11 , G01N33/48
CPC分类号： C12Q1/6883 , C12Q1/686 , C12Q1/6886 , C12Q2600/118 , C12Q2600/154 , C12Q2600/16 , C12Q2523/125 , C12Q2525/301 , C12Q2545/114 , C12Q2563/107 , C12Q2565/1015
摘要： The cMethDNA method of the present invention is a novel modification of the QM-MSP method (U.S. Pat. No. 8,062,849), specifically intended to quantitatively detect tumor DNA (or other circulating DNAs) in fluids such as serum or plasma at the lowest copy number yet reported. Unique compared to any other PCR-based assay, a small number of copies of a synthetic polynucleotide standard (STDgene) is added to an aliquot of patient serum with standards for a plurality of genes of interest (TARGETgene). Once total DNA is purified PCR is performed wherein the STDgene and the TARGETgene are co-amplified with the same external primer set, and the amplicons present in a dilution of the first PCR reaction are subjected to real time PCR, and quantified for each gene. Methods of making the STDgene standards and the use of the cMethDNA methods and kits containing the same are disclosed.

9. 发明申请

WO2013177265A1 A QUANTITATIVE MULTIPLEX METHYLATION SPECIFIC PCR METHOD- cMethDNA, REAGENTS, AND ITS USE 审中-公开
标题翻译：定量多重甲基化特异性PCR方法 - cDNA，试剂及其用途
公开(公告)号：WO2013177265A1
公开(公告)日：2013-11-28
申请号：PCT/US2013042198
申请日：2013-05-22
申请人： UNIV JOHNS HOPKINS
发明人： SUKUMAR SARASWATI , FACKLER MARY JO , TEO WEI WEN , LOPEZ BUJANDA ZOILA ARELI
IPC分类号： C12Q1/68 , C12N15/11 , G01N33/48
CPC分类号： C12Q1/6883 , C12Q1/686 , C12Q1/6886 , C12Q2600/118 , C12Q2600/154 , C12Q2600/16 , C12Q2523/125 , C12Q2525/301 , C12Q2545/114 , C12Q2563/107 , C12Q2565/1015
摘要： The cMethDNA method of the present invention is a novel modification of the QM-MSP method (U.S. Patent No. 8,062,849), specifically intended to quantitatively detect tumor DNA (or other circulating DNAs) in fluids such as serum or plasma at the lowest copy number yet reported. Unique compared to any other PCR-based assay, a small number of copies of a synthetic polynucleotide standard (STDgene) is added to an aliquot of patient serum. In a standard procedure, a cocktail of standards for a plurality of genes of interest (TARGETgene) is added to a sample of serum. Once total DNA is purified and processed, a PCR (multiplex step) is performed wherein the STDgene and the TARGETgene are co-amplified with the same external primer set. In the second nested PCR step, amplicons present in a dilution of the first PCR reaction are subjected to real time PCR, and quantified for each gene in one well by two-color real-time PCR. Products are calculated by absolute quantitation with internal primer sets specific for the methylated TARGETgene and associated STDgene. Methods of making the STDgene standards and the use of the cMethDNA methods and kits containing the same are disclosed.
摘要翻译：本发明的cMethDNA方法是QM-MSP方法（美国专利号8,062,849）的新型修饰，专门旨在定量检测血液或血浆中最低拷贝数的流体中的肿瘤DNA（或其他循环DNA）但报道。与任何其他基于PCR的测定法相比，将少量的合成多核苷酸标准品（STD基因）的拷贝添加到患者血清的等分试样中。在标准方法中，将多种感兴趣基因（TARGETGene）的标准品混合物加入到血清样品中。一旦纯化和处理总DNA，就进行PCR（多重步骤），其中将STD基因和TARGET基因与相同的外部引物组共扩增。在第二嵌套PCR步骤中，将存在于第一PCR反应稀释物中的扩增子进行实时PCR，并通过双色实时PCR对一个孔中的每个基因进行定量。通过绝对定量计算产物，其中特异于甲基化TARGET基因和相关STD基因的内部引物组。公开了制备STD基因标准品的方法和使用含有其的cMethDNA方法和试剂盒。

10. 发明专利

AU2013266341B2 A quantitative multiplex methylation specific PCR method- cMethDNA, reagents, and its use 未知
公开(公告)号：AU2013266341B2
公开(公告)日：2019-01-03
申请号：AU2013266341
申请日：2013-05-22
申请人： UNIV JOHNS HOPKINS
发明人： SUKUMAR SARASWATI , FACKLER MARY JO , TEO WEI WEN , LOPEZ BUJANDA ZOILA ARELI
IPC分类号： C12N15/11 , C12Q1/68 , G01N33/48
摘要： The cMethDNA method of the present invention is a novel modification of the QM-MSP method (U.S. Patent No. 8,062,849), specifically intended to quantitatively detect tumor DNA (or other circulating DNAs) in fluids such as serum or plasma at the lowest copy number yet reported. Unique compared to any other PCR-based assay, a small number of copies of a synthetic polynucleotide standard (STDgene) is added to an aliquot of patient serum. In a standard procedure, a cocktail of standards for a plurality of genes of interest (TARGETgene) is added to a sample of serum. Once total DNA is purified and processed, a PCR (multiplex step) is performed wherein the STDgene and the TARGETgene are co-amplified with the same external primer set. In the second nested PCR step, amplicons present in a dilution of the first PCR reaction are subjected to real time PCR, and quantified for each gene in one well by two-color real-time PCR. Products are calculated by absolute quantitation with internal primer sets specific for the methylated TARGETgene and associated STDgene. Methods of making the STDgene standards and the use of the cMethDNA methods and kits containing the same are disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式